Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Forest Laboratories |
---|---|
Information provided by: | Forest Laboratories |
ClinicalTrials.gov Identifier: | NCT00322153 |
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients with moderate-to-severe Alzheimer's disease on a concurrent acetylcholinesterase inhibitor (AChEI).
Condition | Intervention | Phase |
---|---|---|
Alzheimer's Disease |
Drug: memantine HCL |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type |
Estimated Enrollment: | 600 |
Study Start Date: | June 2005 |
Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
Memantine is a novel therapeutic agent that represents a new class of Alzheimer's disease (AD) treatment options. A once daily (QD) dosing regimen in an AD population would simplify administration for the caregiver. The purpose of this study is to evaluate the safety and efficacy of modified release memantine taken once daily in outpatients with moderate-to-severe AD on a concurrent AChEI.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | MEM-MD-50 |
Study First Received: | May 3, 2006 |
Last Updated: | January 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00322153 |
Health Authority: | United States: Food and Drug Administration |
memantine Alzheimer's disease moderate to severe Alzheimer's disease |
Excitatory Amino Acids Dopamine Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Memantine |
Central Nervous System Diseases Neurodegenerative Diseases Brain Diseases Dementia Cognition Disorders Delirium |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Nervous System Diseases Physiological Effects of Drugs Antiparkinson Agents Excitatory Amino Acid Agents |
Pharmacologic Actions Therapeutic Uses Dopamine Agents Tauopathies Central Nervous System Agents Excitatory Amino Acid Antagonists |